SCHEMBL2106866

SCHEMBL2106866

CC(C)(O)CCCCc1cccc(C=Cc2cccc(C(O)O)c2)c1

nearest known ligand 0.55

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HMGCR P04035 1/20 0.55
VDR P11473 8/20 0.37
CYP24A1 Q07973 2/20 0.37
HDAC4 P56524 1/20 0.35
MEF2D Q14814 1/20 0.35
TAAR1 Q96RJ0 1/20 0.34
CYP4F2 P78329 1/20 0.34
CYP4A11 Q02928 1/20 0.34
PLAU P00749 1/20 0.33
AKR1B10 O60218 1/20 0.33
AKR1B1 P15121 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6154939 0.99 HMGCR (0.54) HMGCRVDRCYP24A1HDAC4MEF2D
SCHEMBL6155341 0.91 HMGCR (0.54) HMGCRVDRCYP24A1HDAC4MEF2D
SCHEMBL2108299 0.90 HMGCR (0.53) HMGCRVDRCYP24A1HDAC4MEF2D
SCHEMBL2106283 0.82 HMGCR (0.57) HMGCRAKR1B10AKR1B1
SCHEMBL2106865 0.82 HMGCR (0.57) HMGCRVDRCYP24A1HDAC4MEF2D
SCHEMBL2108149 0.82 HMGCR (0.57) HMGCRAKR1B10AKR1B1
SCHEMBL2106863 0.82 HMGCR (0.57) HMGCRVDRCYP24A1HDAC4MEF2D
SCHEMBL2107875 0.82 HMGCR (0.57) HMGCRVDRCYP24A1AKR1B10AKR1B1
SCHEMBL2107876 0.82 HMGCR (0.57) HMGCRVDRCYP24A1AKR1B10AKR1B1
SCHEMBL2108148 0.82 HMGCR (0.57) HMGCRAKR1B10AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1124779-B1 VITAMIN D ANALOGUES GALDERMA RES & DEV (FR) 2005-02-02 EP claimed
US-6689922-B1 BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-10 US claimed
US-11730682-B2 Self-standing cosmetic sheet L'OREAL (FR) 2023-08-22 US disclosed
EP-2836187-B1 SELF-STANDING COSMETIC SHEET OREAL (FR) 2021-12-08 EP disclosed
US-20180235849-A1 SELF-STANDING COSMETIC SHEET L'OREAL (FR) 2018-08-23 US disclosed
US-9949897-B2 Self-standing cosmetic sheet L'OREAL (FR) 2018-04-24 US disclosed
US-20150209243-A1 SELF-STANDING COSMETIC SHEET L'OREAL (FR) 2015-07-30 US disclosed
EP-2836187-A1 SELF-STANDING COSMETIC SHEET L'Oréal (FR) 2015-02-18 EP disclosed
EP-1658838-B1 Emulsification system for use in cosmetics ORÉAL L (FR) 2014-07-02 EP disclosed
WO-2013153678-A1 SELF-STANDING COSMETIC SHEET L'OREAL (FR) 2013-10-17 WO disclosed
US-8158136-B2 Emulsification system for use in cosmetics L'ORÉAL (FR) 2012-04-17 US disclosed
US-20060039936-A1 Emulsification system for use in cosmetics L'OREAL (FR) 2006-02-23 US disclosed
US-20050169945-A1 Composition for protecting keratin material, process of making, uses thereof L'OREAL (FR) 2005-08-04 US disclosed
EP-1559398-A1 Process for preparing a composition for the cosmetic treatment of keratinous materials on the basis of a pressurised fluid and vitamins L'OREAL (FR) 2005-08-03 EP disclosed
EP-1124779-B1 VITAMIN D ANALOGUES GALDERMA RES & DEV (FR) 2005-02-02 EP disclosed
US-6689922-B1 BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-10 US disclosed
US-20020197289-A1 Compositions and methods for combating the appearance of ageing L'OREAL (FR) 2002-12-26 US disclosed
EP-1262168-A1 Composition containing fibres to combat the skin aging process L'OREAL (FR) 2002-12-04 EP disclosed
EP-1124779-A1 VITAMIN D ANALOGUES Galderma Research & Development, S.N.C. (FR) 2001-08-22 EP disclosed
WO-2000026167-A1 VITAMIN D ANALOGUES GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2000-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020197289-A1 Compositions and methods for combating the appearance of ageing CYP24A1, CYP27B1, CYP2R1 HMGCR 283/4885VDR 4/4885CYP24A1 1/4885
US-20150209243-A1 SELF-STANDING COSMETIC SHEET CUTA, SUCLG1, SIGLEC7 HMGCR 691/4885VDR 4601/4885CYP24A1 3786/4885
US-20180235849-A1 SELF-STANDING COSMETIC SHEET CUTA, DSG1, SUCLG1 HMGCR 565/4885VDR 4085/4885CYP24A1 2442/4885
US-11730682-B2 Self-standing cosmetic sheet CUTA, DSG1, SUCLG1 HMGCR 565/4885VDR 4085/4885CYP24A1 2442/4885
US-20050169945-A1 Composition for protecting keratin material, process of making, uses thereof KRT18, PROC, CUTA HMGCR 1113/4885VDR 514/4885CYP24A1 317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.